Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Olivier Rixe"'
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Timothy F. Cloughesy, Andrew B. Lassman, Ray Li, Annick Desjardins, Shilpa Alekar, Carrie T. Taylor, David A. Reardon, Olivier Rixe, Jason H. Williams
Publikováno v:
Investigational new drugs. 38(6)
Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy i
Autor:
Anthony J. Olszanski, Olivier Rixe, Olugbenga Olowokure, Séverine Doroumian, John C. Morris, Jian Y. Yin, Roger B. Cohen, Liji Shen, Igor Puzanov, Patricia LoRusso
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Autor:
Laurent Kassalow, Jean François Dedieu, Monica M. Mita, John C. Morris, James L. Wade, John Sarantopoulos, Claudine Wack, Alain C. Mita, A. Craig Lockhart, Olivier Rixe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:1113-1124
Cabazitaxel is primarily metabolized by CYP3A. This study evaluated the impact of moderate/strong CYP3A inhibitors [aprepitant (Study Part 2); ketoconazole (Study Part 3)] or strong CYP3A inducers [rifampin (Study Part 4)] on the pharmacokinetics of
Autor:
A. Caty, Stéphane Culine, Rémi Delva, Agnès Laplanche, Frank Priou, Philippe Beuzeboc, Christine Chevreau, Frederic Rolland, Pierre Kerbrat, Lionnel Geoffrois, Jean-pierre Malhaire, Olivier Rixe, Karim Fizazi, Marie-Stephanie Aubelle
Publikováno v:
European Urology. 65:381-386
Background Whether patients with good prognosis and intermediate/poor prognosis advanced seminoma should be treated differently has not been defined. Objective To assess a risk-adapted chemotherapy regimen in patients with advanced seminoma. Design,
Autor:
Tracy Y. Ansay, Ronald E. Warnick, El Mustapha Bahassi, Christopher M. McPherson, Ahmad Zarzour, Olivier Rixe, Mohamad Adham Salkeni
Publikováno v:
Journal of Neuro-Oncology. 115:27-35
Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens including surgical resection, radiation and chemotherapy. EGFRvIII is a truncated extracellular mutant of
Autor:
El Mustapha Bahassi, Li Deng, Keith M. Wilson, Trisha Wise-Draper, Jiang Wang, Susanne I. Wells, Colleen N. Darnell, Olivier Rixe, Peter J. Stambrook, Ya-Qin Li
Publikováno v:
European Journal of Cancer. 49:2345-2355
Background Cetuximab is an epidermal growth factor receptor (EGFR)-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer, but no predictive biomarker
Autor:
B. Billemont, Eric Van Cutsem, David Khayat, Karen Soussan-Lazard, Sylvaine Cartot-Cotton, Olivier Rixe, Sabine Tejpar, Jean-Baptiste Meric, Sylvie Assadourian, Chris Verslype
Publikováno v:
European Journal of Cancer. 49:17-24
Background To determine dose-limiting toxicities (DLTs), recommended phase II trial dose (RPTD), safety, preliminary antitumour activity and pharmacokinetics of intravenous aflibercept with irinotecan, 5-fluorouracil and leucovorin (LV5FU2). Patients
Autor:
David I. Quinn, Pierre François Clot, Jian Yin, James L. Wade, A. Craig Lockhart, James W. Mier, Wenping Zhang, John Sarantopoulos, Alain C. Mita, John C. Morris, Aiwu He, Olivier Rixe, Jimmy J. Hwang, Chung-Tsen Hsueh, Claudine Wack
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Cabazitaxel has not been studied in patients with hepatic impairment (HI). This phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI. Methods Patients with advanced, non-hematologic cancer, and normal hepatic fun